Biomonster
Junior member
- Messages
- 21
- Likes
- 0
Stock hit new 52W high yesterday .....
A LOT of BIG milestones are around the corner which likely will push the stock toward 200p and higher . The most important milestones are the FDA Decision for Alkindi in September and the EMA Decision for Chronocort in early Q1 . STRONG BUY stock likely to run higher as we move closer to US-FDA approval .
Valuation 344p
The increased use of commercial partners has caused us to reassess our DCF analysis, moving it more towards a distribution and royalty-based model. Our original DCF valuation,based on clearly stated assumptions,was published on 25 April 2019.The NPV of the cash flows that could be generated from DNL’s first two products has changed from £389m to £455m.Risk-adjustment to take account of the different stages of development in different territories reduces this to £298m, or 344p per share
Market Cap £76 million
Cash balance £15 million or Cash untill end 2021
Price 62 p
Alkindi approval in Australia expected this Quarter
Alkindi approval in Israel expected this Quarter
FDA decision for Alkindi on September 29 ( DNL will receive $2.5 M on first commercial sale expected in Q4 )
EMA Decision for Chronocort expected in early Q1 2021
US-Partnership for Chronocort (Phase 3 ready) in 2H 2020
A LOT of BIG milestones are around the corner which likely will push the stock toward 200p and higher . The most important milestones are the FDA Decision for Alkindi in September and the EMA Decision for Chronocort in early Q1 . STRONG BUY stock likely to run higher as we move closer to US-FDA approval .
Valuation 344p
The increased use of commercial partners has caused us to reassess our DCF analysis, moving it more towards a distribution and royalty-based model. Our original DCF valuation,based on clearly stated assumptions,was published on 25 April 2019.The NPV of the cash flows that could be generated from DNL’s first two products has changed from £389m to £455m.Risk-adjustment to take account of the different stages of development in different territories reduces this to £298m, or 344p per share
Market Cap £76 million
Cash balance £15 million or Cash untill end 2021
Price 62 p
Alkindi approval in Australia expected this Quarter
Alkindi approval in Israel expected this Quarter
FDA decision for Alkindi on September 29 ( DNL will receive $2.5 M on first commercial sale expected in Q4 )
EMA Decision for Chronocort expected in early Q1 2021
US-Partnership for Chronocort (Phase 3 ready) in 2H 2020
